Company
Botanix Pharmaceuticals Limited
Headquarters: North Perth, WA, Australia
Employees: 6
Market Cap
A$615.1 Million
AUD as of July 1, 2024
US$409.7 Million
Botanix Pharmaceuticals Limited Categories
Australia Healthcare BiotechnologyAustralia Healthcare Australia Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. Its product pipeline include BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase Ib clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in North Perth, Australia.
Financials
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | A$437,215 |
| EBITDA | A$-10,021,756 |
| Gross Profit TTM | A$102,934 |
| Profit Margin | 0.00% |
| Operating Margin | -1462.26% |
| Quarterly Revenue Growth | -89.80% |
Stocks & Indices
Botanix Pharmaceuticals Limited has the following listings and related stock indices.
Stock: ASX: BOT wb_incandescent